Novaliq Presents Results of Cyclasol in P-III (ESSENCE-2) Trial for the Treatment of Dry Eye Disease at ASCRS 2022
Shots:
- The P-III (ESSENCE-2) trial evaluating CyclASol vs vehicle in 834 patients with DED not responding to artificial tears
- The results showed that CyclASol has consistent & superior therapeutic effects on the ocular surface in patients with DED, 71.6% had a ≥ 3-grade improvement in tCFS @4wks. & the proportion of responders was higher compared to vehicles with superior relief of blurred vision in patients with high central staining scores
- The therapy showed that 78.6% rated their satisfaction with CyclASol & has excellent safety & tolerability profile, improvement in tear production & variety of symptoms over non-responders @Day 29, change from baseline in tCFS was significant in CyclASol @Day 15 & 29
Ref: PRNewswire | Image: Novaliq
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
